Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oramed PharmaceuticalsORMP +0.84%32 3-1 Month Momentum % is -6.06% as of Aug. 19, 2026. GuruFocus rates ORMP with a GF Score™ of 32/100. The stock has 5 warning signs investors should review. Among 1,386 Biotechnology companies, Oramed Pharmaceuticals ranks better than 50.14% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-19), Oramed Pharmaceuticals's 3-1 Month Momentum % is -6.06%.
The industry rank for Oramed Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
ORMP's 3-1 Month Momentum % is ranked better than 50.14% of 1386
companies
in the Biotechnology industry
Industry Median: -6.185
vs ORMP: -6.06
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Oramed Pharmaceuticals 3-1 Month Momentum % Related Terms
ORMP vs CAMP, PYXS, ALEC: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Oramed Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oramed Pharmaceuticals 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oramed Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Oramed Pharmaceuticals's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oramed Pharmaceuticals (ORMP) has a 3-1 Month Momentum % of -6.06% as of Aug. 19, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Oramed Pharmaceuticals and its competitors. According to the industry distribution chart, Oramed Pharmaceuticals ranks #691 out of 1386 companies in the Biotechnology industry, placing it in the top 49.9%.
Is Oramed Pharmaceuticals' 3-1 Month Momentum % too high?
Oramed Pharmaceuticals' current 3-1 Month Momentum % is -6.06%. Based on the distribution chart, Oramed Pharmaceuticals ranks #691 out of 1386 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oramed Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Oramed Pharmaceuticals' 3-1 Month Momentum % compare to CAMP and PYXS?
According to the Biotechnology industry distribution chart, Oramed Pharmaceuticals ranks #691 out of 1386 companies for 3-1 Month Momentum %. This puts Oramed Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Oramed Pharmaceuticals and its competitors. Oramed Pharmaceuticals's current 3-1 Month Momentum % is -6.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oramed Pharmaceuticals stock overvalued right now?
Oramed Pharmaceuticals (ORMP) has a current 3-1 Month Momentum % of -6.06%. The current 3-1 Month Momentum % is -6.06%. Oramed Pharmaceuticals' overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Oramed Pharmaceuticals (ORMP), the current 3-1 Month Momentum % is -6.06% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
32GF Score
Get the complete analysis for ORMP
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORMP has been successfully added to your 
